Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067365 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
A Phase 3 study of Secondary Hypogonadism, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
- 18
- Study locations
NCT01067365 is a Phase 3 study of Secondary Hypogonadism that has completed, run by Repros Therapeutics. The registered enrollment target is 104 participants. The trial reports 18 study locations across 13 states.
The verdict
NCT01067365, a Phase 3 study of Secondary Hypogonadism, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
- 18
- Study locations
Study Summary
Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.
Conditions Studied
Interventions
- DRUG Androxal
Study Locations (18)
California
- Northern California Research Corp - Carmichael
- Prime-Care Clinical Research - Mission Viejo
- Harbor-UCLA Medical Center - Torrance
Alabama
- Alabama Clinical Therapeutics, LLC - Birmingham
- Medial Affiliated Research Center, Inc. - Huntsville
Nevada
- Office of Michael Mall, MD - Las Vegas
- Office of Stephen Miller, MD - Las Vegas
New Jersey
- Advanced Biomedical Research, Inc. - Hackensack
- Office of Gary S. Karlin, MD - Lawrenceville
Connecticut
- Chase Medical Research, LLC - Waterbury
Florida
- Southeastern Research Group, Inc. - Tallahassee
Indiana
- Northeast Indiana Research, LLC - Fort Wayne
Kentucky
- Commonweatlh Biomedical Research - Madisonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01067365
The ClinicalTrials.gov registry entry for NCT01067365 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Secondary Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Androxal is the first listed.
NCT01067365 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, Alabama, Nevada.
Frequently Asked Questions
What is clinical trial NCT01067365 about?
NCT01067365 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism". Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.
What is the current status of trial NCT01067365?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2006-03. Estimated completion is 2007-05.
What conditions does trial NCT01067365 study?
This clinical trial studies the following conditions: Secondary Hypogonadism.
What interventions are being tested in trial NCT01067365?
The interventions under investigation include: Androxal (DRUG).
Who is sponsoring clinical trial NCT01067365?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01067365 being conducted?
This trial has 18 study locations across Alabama, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.